Trial Outcomes & Findings for Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant. (NCT NCT01952470)

NCT ID: NCT01952470

Last Updated: 2019-08-28

Results Overview

A measure of ventilation inhomogeneity as measured during multiple breath washout (MBW) of inert tracer gases. It has been shown that this test is a potentially more sensitive measure of peripheral airway obstruction than regular spirometry in short term (4 week) mucolytic interventional studies in pediatric Cystic Fibrosis (CF)(17-18). This test would be performed within the respiratory physiology lung function laboratory on site at all assessment points, by an assessor who is blinded to group allocation for follow up data collection. Conventionally used primary endpoints in this population, such as regular spirometry(3), may be unable to detect between group differences without large sample sizes and long treatment durations. Based on current evidence from non-lung transplant populations, LCI has been able to show short-term change, whereas regular spirometry has not shown change(17-18).

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

32 participants

Primary outcome timeframe

1 month, 3 months

Results posted on

2019-08-28

Participant Flow

Participant milestones

Participant milestones
Measure
Dornase Alfa
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Overall Study
STARTED
16
16
Overall Study
ITT Analysis
16
16
Overall Study
Discontinued Intervention
2
1
Overall Study
Death
1
1
Overall Study
Missing Baseline LCI 2% Data.
0
2
Overall Study
Missing 1+3 Month LCI 2% Data.
2
1
Overall Study
Missing 3 Month LCI 2% Data.
1
0
Overall Study
COMPLETED
13
13
Overall Study
NOT COMPLETED
3
3

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Dornase Alfa
n=16 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alpha (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=16 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Total
n=32 Participants
Total of all reporting groups
Age, Continuous
52.88 years
STANDARD_DEVIATION 10.77 • n=16 Participants
47.56 years
STANDARD_DEVIATION 15.99 • n=16 Participants
50.22 years
STANDARD_DEVIATION 13.68 • n=32 Participants
Sex: Female, Male
Female
5 Participants
n=16 Participants
9 Participants
n=16 Participants
14 Participants
n=32 Participants
Sex: Female, Male
Male
11 Participants
n=16 Participants
7 Participants
n=16 Participants
18 Participants
n=32 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
Australia
16 participants
n=16 Participants
16 participants
n=16 Participants
32 participants
n=32 Participants
Days since transplant
1162.50 Days
n=16 Participants
1497 Days
n=16 Participants
1275 Days
n=32 Participants
Body mass index
24.94 kg/m2
STANDARD_DEVIATION 4.95 • n=16 Participants
23.96 kg/m2
STANDARD_DEVIATION 6.10 • n=16 Participants
24.45 kg/m2
STANDARD_DEVIATION 5.48 • n=32 Participants
Chronic Lung Allograft Dysfunction (CLAD) diagnosis at baseline
2 Participants
n=16 Participants
5 Participants
n=16 Participants
7 Participants
n=32 Participants
Sinus disease diagnosis at baseline
4 Participants
n=16 Participants
2 Participants
n=16 Participants
6 Participants
n=32 Participants
Gastro-Oesophageal Reflux Disease (GORD) diagnosis at baseline
12 Participants
n=16 Participants
13 Participants
n=16 Participants
25 Participants
n=32 Participants
Initial inpatient length of stay (LOS)
6.5 Days
n=16 Participants
7.0 Days
n=16 Participants
7.0 Days
n=32 Participants
C-Reactive Protein (CRP)
6 mg/L
n=16 Participants
29.50 mg/L
n=16 Participants
9.00 mg/L
n=32 Participants
Multiple Breath Washout (MBW)
Sacin
0.337 Index
STANDARD_DEVIATION 0.173 • n=16 Participants • Baseline MBW data lost due to technical error (IS n=2)
0.354 Index
STANDARD_DEVIATION 0.218 • n=14 Participants • Baseline MBW data lost due to technical error (IS n=2)
0.345 Index
STANDARD_DEVIATION 0.191 • n=30 Participants • Baseline MBW data lost due to technical error (IS n=2)
Multiple Breath Washout (MBW)
Scond
0.035 Index
STANDARD_DEVIATION 0.026 • n=16 Participants • Baseline MBW data lost due to technical error (IS n=2)
0.026 Index
STANDARD_DEVIATION 0.023 • n=14 Participants • Baseline MBW data lost due to technical error (IS n=2)
0.031 Index
STANDARD_DEVIATION 0.025 • n=30 Participants • Baseline MBW data lost due to technical error (IS n=2)
Lung Clearance Index (2%)
10.31 Index
STANDARD_DEVIATION 2.38 • n=16 Participants • Baseline data lost due to technical error (Isotonic saline (IS) group n=2)
11.05 Index
STANDARD_DEVIATION 2.40 • n=14 Participants • Baseline data lost due to technical error (Isotonic saline (IS) group n=2)
10.65 Index
STANDARD_DEVIATION 2.38 • n=30 Participants • Baseline data lost due to technical error (Isotonic saline (IS) group n=2)
Forced Expiratory Ratio (FER)
61.56 Ratio
STANDARD_DEVIATION 13.28 • n=16 Participants
69.31 Ratio
STANDARD_DEVIATION 12.05 • n=16 Participants
65.44 Ratio
STANDARD_DEVIATION 13.08 • n=32 Participants
Forced Expiratory Volume in 1 second (FEV1)
62.50 Percent (%)
STANDARD_DEVIATION 25.11 • n=16 Participants
53.00 Percent (%)
STANDARD_DEVIATION 18.55 • n=16 Participants
57.75 Percent (%)
STANDARD_DEVIATION 22.25 • n=32 Participants
Forced Vital Capacity (FVC)
75.18 Percent (%)
STANDARD_DEVIATION 19.29 • n=16 Participants
59.81 Percent (%)
STANDARD_DEVIATION 14.07 • n=16 Participants
67.81 Percent (%)
STANDARD_DEVIATION 18.49 • n=32 Participants
Functional Residual Capacity
2.32 Liters (L)
STANDARD_DEVIATION 0.86 • n=16 Participants • Baseline data lost due to technical error (Isotonic saline (IS) group n=2)
1.83 Liters (L)
STANDARD_DEVIATION 0.76 • n=14 Participants • Baseline data lost due to technical error (Isotonic saline (IS) group n=2)
2.09 Liters (L)
STANDARD_DEVIATION 0.84 • n=30 Participants • Baseline data lost due to technical error (Isotonic saline (IS) group n=2)
Leicester Cough Questionnaire (LCQ)
Physical
4.53 units on a scale
STANDARD_DEVIATION 1.04 • n=16 Participants
4.69 units on a scale
STANDARD_DEVIATION 1.17 • n=16 Participants
4.61 units on a scale
STANDARD_DEVIATION 1.09 • n=32 Participants
Leicester Cough Questionnaire (LCQ)
Psychological
4.68 units on a scale
STANDARD_DEVIATION 1.35 • n=16 Participants
4.95 units on a scale
STANDARD_DEVIATION 1.69 • n=16 Participants
4.81 units on a scale
STANDARD_DEVIATION 1.51 • n=32 Participants
Leicester Cough Questionnaire (LCQ)
Social
4.98 units on a scale
STANDARD_DEVIATION 1.57 • n=16 Participants
4.95 units on a scale
STANDARD_DEVIATION 1.62 • n=16 Participants
4.97 units on a scale
STANDARD_DEVIATION 1.57 • n=32 Participants
Leicester Cough Questionnaire (LCQ)
Total
14.44 units on a scale
STANDARD_DEVIATION 3.88 • n=16 Participants
14.60 units on a scale
STANDARD_DEVIATION 4.25 • n=16 Participants
14.52 units on a scale
STANDARD_DEVIATION 4.00 • n=32 Participants
St George's Respiratory Questionnaire (SGRQ)
Symptom
55.51 units on a scale
STANDARD_DEVIATION 19.59 • n=16 Participants
53.35 units on a scale
STANDARD_DEVIATION 16.92 • n=16 Participants
54.43 units on a scale
STANDARD_DEVIATION 18.04 • n=32 Participants
St George's Respiratory Questionnaire (SGRQ)
Activity
50.37 units on a scale
STANDARD_DEVIATION 29.25 • n=16 Participants
58.25 units on a scale
STANDARD_DEVIATION 21.34 • n=16 Participants
54.31 units on a scale
STANDARD_DEVIATION 25.50 • n=32 Participants
St George's Respiratory Questionnaire (SGRQ)
Impact
30.53 units on a scale
STANDARD_DEVIATION 17.61 • n=16 Participants
34.06 units on a scale
STANDARD_DEVIATION 14.39 • n=16 Participants
32.30 units on a scale
STANDARD_DEVIATION 15.92 • n=32 Participants
St George's Respiratory Questionnaire (SGRQ)
Total
40.64 units on a scale
STANDARD_DEVIATION 19.78 • n=16 Participants
44.69 units on a scale
STANDARD_DEVIATION 14.82 • n=16 Participants
42.66 units on a scale
STANDARD_DEVIATION 17.32 • n=32 Participants

PRIMARY outcome

Timeframe: 1 month, 3 months

Population: Dropout

A measure of ventilation inhomogeneity as measured during multiple breath washout (MBW) of inert tracer gases. It has been shown that this test is a potentially more sensitive measure of peripheral airway obstruction than regular spirometry in short term (4 week) mucolytic interventional studies in pediatric Cystic Fibrosis (CF)(17-18). This test would be performed within the respiratory physiology lung function laboratory on site at all assessment points, by an assessor who is blinded to group allocation for follow up data collection. Conventionally used primary endpoints in this population, such as regular spirometry(3), may be unable to detect between group differences without large sample sizes and long treatment durations. Based on current evidence from non-lung transplant populations, LCI has been able to show short-term change, whereas regular spirometry has not shown change(17-18).

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=14 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=15 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Lung Clearance Index 2% (LCI2%)
1 month
10.68 Index (change)
Standard Deviation 1.97
11.65 Index (change)
Standard Deviation 2.33
Lung Clearance Index 2% (LCI2%)
3 months
10.09 Index (change)
Standard Deviation 2.19
11.19 Index (change)
Standard Deviation 2.73

SECONDARY outcome

Timeframe: 1 month, 3 months

Population: Dropout

Multiple breath washout is a sensitive measure of respiratory function performed with the subject in a seated position, breathing a fixed tidal volume (1L) of inert gas (nitrogen) from functional residual capacity (FRC) via mouthpiece. Two common outcomes of MBW are Sacin, a measure of gas mixing at the diffusion front, or acinar entrance in the airways, and Scond, in the proximal, conductive zones. An increase in either Sacin or Scond represents an increase in ventilation heterogeneity (deterioration). Both increase with age, normal values are non-zero between 0-0.25(Sacin) and 0-0.1(Scond).

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=14 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=15 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Multiple Breath Washout (MBW)
Scond 3 months
0.033 Gas mixing index (Sacin / Scond)
Standard Deviation 0.017
0.021 Gas mixing index (Sacin / Scond)
Standard Deviation 0.027
Multiple Breath Washout (MBW)
Sacin 1 month
0.348 Gas mixing index (Sacin / Scond)
Standard Deviation 0.155
0.383 Gas mixing index (Sacin / Scond)
Standard Deviation 0.227
Multiple Breath Washout (MBW)
Sacin 3 months
0.354 Gas mixing index (Sacin / Scond)
Standard Deviation 0.249
0.356 Gas mixing index (Sacin / Scond)
Standard Deviation 0.188
Multiple Breath Washout (MBW)
Scond 1 month
0.045 Gas mixing index (Sacin / Scond)
Standard Deviation 0.037
0.026 Gas mixing index (Sacin / Scond)
Standard Deviation 0.037

SECONDARY outcome

Timeframe: 1 month, 3 months

Population: Dropout

Volume of air remaining in the lungs after normal expiration.

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=14 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=15 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Functional Residual Capacity (FRC)
1 month
2.03 Liters (L)
Standard Deviation 0.96
1.80 Liters (L)
Standard Deviation 0.81
Functional Residual Capacity (FRC)
3 months
2.22 Liters (L)
Standard Deviation 1.01
1.78 Liters (L)
Standard Deviation 0.76

SECONDARY outcome

Timeframe: 1 month, 3 months.

Population: Dropout

FEV1 is the maximal amount of air you can forcefully exhale in one second.

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=15 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=15 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Forced Expiratory Volume in 1 Second (FEV1) Liters
FEV1 L 1 month
2.11 Liters (L) - change
Standard Deviation 0.68
1.76 Liters (L) - change
Standard Deviation 0.81
Forced Expiratory Volume in 1 Second (FEV1) Liters
FEV1 L 3 months
1.91 Liters (L) - change
Standard Deviation 0.88
1.78 Liters (L) - change
Standard Deviation 0.82

SECONDARY outcome

Timeframe: 1 month, 3 months

Population: Dropout

FEV1 is the maximal amount of air you can forcefully exhale in one second.

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=15 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=15 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Forced Expiratory Volume in 1 Second (FEV1) Percent.
1 month
69.33 Percent (%)
Standard Deviation 25.35
58.33 Percent (%)
Standard Deviation 21.44
Forced Expiratory Volume in 1 Second (FEV1) Percent.
3 months
63.00 Percent (%)
Standard Deviation 27.94
57.60 Percent (%)
Standard Deviation 22.35

SECONDARY outcome

Timeframe: 1 month, 3 months

Population: Dropout

Forced vital Capacity (FVC) is a measure of the amount of air someone can forcibly expel out of the lungs after taking a breath to fill the lungs as much as possible.

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=15 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=15 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Forced Vital Capacity (FVC) Liters
1 month
3.21 Liters (L)
Standard Deviation 0.73
2.46 Liters (L)
Standard Deviation 0.91
Forced Vital Capacity (FVC) Liters
3 months
2.96 Liters (L)
Standard Deviation 0.75
2.50 Liters (L)
Standard Deviation 0.89

SECONDARY outcome

Timeframe: 1 month, 3 months

Population: Dropout

Forced vital Capacity (FVC) is a measure of the amount of air someone can forcibly expel out of the lungs after taking a breath to fill the lungs as much as possible.

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=15 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=15 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Forced Vital Capacity (FVC) Percent
3 months
74.41 Percent (%)
Standard Deviation 17.02
63.73 Percent (%)
Standard Deviation 16.88
Forced Vital Capacity (FVC) Percent
1 month
79.40 Percent (%)
Standard Deviation 18.07
62.07 Percent (%)
Standard Deviation 16.34

SECONDARY outcome

Timeframe: 1 month, 3 months

Population: Dropout

FER represents the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC).

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=15 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=15 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Forced Expiratory Ratio (FER)
1 month
66.33 Ratio
Standard Deviation 14.03
70.87 Ratio
Standard Deviation 11.95
Forced Expiratory Ratio (FER)
3 months
62.79 Ratio
Standard Deviation 17.13
70.27 Ratio
Standard Deviation 13.67

SECONDARY outcome

Timeframe: 1 month, 3 months.

Population: Dropout / loss of data.

Cough specific quality of life questionnaire. The LCQ is a 19-question tool, validated in chronic lung disease other than lung transplant(19). Scale 1-7 for physical, psychological, social. Combined score of 3-21 for total. Lower=worse.

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=16 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=15 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Leicester Cough Questionnaire (LCQ) - Change
Physical 1 month
5.73 score on a scale
Standard Deviation 0.86
5.12 score on a scale
Standard Deviation 0.90
Leicester Cough Questionnaire (LCQ) - Change
Physical 3 months
5.56 score on a scale
Standard Deviation 1.25
5.69 score on a scale
Standard Deviation 0.89
Leicester Cough Questionnaire (LCQ) - Change
Psychological 1 month
6.32 score on a scale
Standard Deviation 0.87
5.87 score on a scale
Standard Deviation 0.96
Leicester Cough Questionnaire (LCQ) - Change
Psychological 3 months
6.03 score on a scale
Standard Deviation 1.35
6.05 score on a scale
Standard Deviation 0.95
Leicester Cough Questionnaire (LCQ) - Change
Social 1 month
6.33 score on a scale
Standard Deviation 0.77
5.75 score on a scale
Standard Deviation 0.97
Leicester Cough Questionnaire (LCQ) - Change
Social 3 months
6.12 score on a scale
Standard Deviation 1.18
6.07 score on a scale
Standard Deviation 0.98
Leicester Cough Questionnaire (LCQ) - Change
Total 1 month
17.26 score on a scale
Standard Deviation 4.62
16.72 score on a scale
Standard Deviation 2.51
Leicester Cough Questionnaire (LCQ) - Change
Total 3 months
17.70 score on a scale
Standard Deviation 3.69
17.81 score on a scale
Standard Deviation 2.71

SECONDARY outcome

Timeframe: 1 month, 3 months.

Population: Dropout / lost data.

The SGRQ is a 2-part questionnaire, validated in chronic lung disease other than lung transplant(20). 50 items, 76 weighted responses. Scores range 0-100, higher=worse.

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=16 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=15 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
St. George's Respiratory Questionnaire (SGRQ) - Change
Symptom 3 months
48.52 units on a scale
Standard Deviation 17.54
51.47 units on a scale
Standard Deviation 23.03
St. George's Respiratory Questionnaire (SGRQ) - Change
Activity 1 month
40.82 units on a scale
Standard Deviation 25.31
57.38 units on a scale
Standard Deviation 22.59
St. George's Respiratory Questionnaire (SGRQ) - Change
Activity 3 months
53.18 units on a scale
Standard Deviation 32.15
53.81 units on a scale
Standard Deviation 29.58
St. George's Respiratory Questionnaire (SGRQ) - Change
Impact 1 month
20.59 units on a scale
Standard Deviation 17.47
30.72 units on a scale
Standard Deviation 13.49
St. George's Respiratory Questionnaire (SGRQ) - Change
Impact 3 months
25.96 units on a scale
Standard Deviation 21.54
33.90 units on a scale
Standard Deviation 22.16
St. George's Respiratory Questionnaire (SGRQ) - Change
Total 1 month
32.50 units on a scale
Standard Deviation 17.98
43.58 units on a scale
Standard Deviation 14.28
St. George's Respiratory Questionnaire (SGRQ) - Change
Total 3 months
37.97 units on a scale
Standard Deviation 22.75
40.81 units on a scale
Standard Deviation 22.63
St. George's Respiratory Questionnaire (SGRQ) - Change
Symptom 1 month
55.65 units on a scale
Standard Deviation 19.25
61.93 units on a scale
Standard Deviation 17.45

SECONDARY outcome

Timeframe: Across study period (3 months).

Number of days spent in the acute inpatient setting.

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=16 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=16 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Inpatient Days
All cause - intervention
8.67 Days
Standard Deviation 3.88
12.50 Days
Standard Deviation 15.76
Inpatient Days
All cause - follow-up
8.09 Days
Standard Deviation 7.73
11.38 Days
Standard Deviation 10.07
Inpatient Days
Respiratory - intervention
9.20 Days
Standard Deviation 4.09
21.50 Days
Standard Deviation 20.51
Inpatient Days
Respiratory - follow-up
9.83 Days
Standard Deviation 9.24
14.33 Days
Standard Deviation 9.99

SECONDARY outcome

Timeframe: Over study period (3 months).

Antibiotic use for the treatment of lower respiratory tract infections (LRTI) only.

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=16 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=16 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Oral, Inhaled or Intravenous Antibiotic (IVAB) Days.
Intervention phase
23.50 Days
Interval 14.0 to 30.0
25.00 Days
Interval 17.5 to 29.75
Oral, Inhaled or Intravenous Antibiotic (IVAB) Days.
Follow-up phase
14.00 Days
Interval 0.0 to 32.25
10.50 Days
Interval 0.0 to 34.5

SECONDARY outcome

Timeframe: Over study period (3 months).

Number of admissions to the acute setting.

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=16 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=16 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Number of Hospitalizations
All cause - intervention
8 Hospitalizations
4 Hospitalizations
Number of Hospitalizations
All cause - follow-up
12 Hospitalizations
8 Hospitalizations
Number of Hospitalizations
Respiratory - intervention
7 Hospitalizations
2 Hospitalizations
Number of Hospitalizations
Respiratory - follow-up
6 Hospitalizations
6 Hospitalizations

SECONDARY outcome

Timeframe: 1 month, 3 months.

Population: Data only available when routinely collected.

An inflammatory marker measured with routine blood tests on admission with LRTI. Taken during inpatient (IP) stay and routinely on outpatient (OP) follow-up. Existing / available data only will be used - no extra routine bloods will be taken on account of study inclusion.

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=10 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=10 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
C-reactive Protein (CRP)
1 month
1.00 mg/L (change)
Interval 1.0 to 9.25
2.50 mg/L (change)
Interval 1.0 to 32.0
C-reactive Protein (CRP)
3 months
12 mg/L (change)
Interval 1.0 to 24.0
1.00 mg/L (change)
Interval 1.0 to 70.5

SECONDARY outcome

Timeframe: Daily up to 3 months.

Self-reported symptom severity, used as a daily patient diary. The BCSS is a 12 point self-reported symptom severity score, consisting of 3 sections concerning how much difficulty the subject is having with breathing; subjective cough symptoms and trouble caused by sputum, each scoring between 0-4, combining to a total score of 0-12 (higher=worse). This scale is validated for daily use in Chronic Obstructive Pulmonary Disease (COPD)(21). An exacerbation was defined as an increase in BCSS\>1 with ≥5 days preceding stability.

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=16 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=16 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Breathlessness, Cough and Sputum Scale (BCSS) - Exacerbations
Intervention phase
0.94 Exacerbations
Standard Deviation 1.00
1.07 Exacerbations
Standard Deviation 1.00
Breathlessness, Cough and Sputum Scale (BCSS) - Exacerbations
Follow-up phase
2.64 Exacerbations
Standard Deviation 2.02
3.62 Exacerbations
Standard Deviation 2.02

SECONDARY outcome

Timeframe: Daily up to 3 months.

Population: Dropout / loss of data.

Sputum colour chart. Sputum colour has been shown to correlate with physiological infection in other chronic lung disease groups(22).

Outcome measures

Outcome measures
Measure
Dornase Alfa
n=16 Participants
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=14 Participants
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
BronkoTest (Sputum Colour) - Purulent Sputum Days
Intervention phase
11.50 days
Interval 5.5 to 22.5
8.50 days
Interval 4.0 to 18.25
BronkoTest (Sputum Colour) - Purulent Sputum Days
Follow-up phase
4.50 days
Interval 0.0 to 22.5
6.00 days
Interval 1.5 to 15.0

Adverse Events

Dornase Alfa

Serious events: 0 serious events
Other events: 4 other events
Deaths: 1 deaths

Isotonic Saline

Serious events: 0 serious events
Other events: 3 other events
Deaths: 1 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Dornase Alfa
n=16 participants at risk
Once daily, 2.5ml inhaled dornase alfa. Dornase Alfa: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Isotonic Saline
n=16 participants at risk
Once daily, 5ml inhaled 0.9% normal saline. Isotonic Saline.: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Respiratory, thoracic and mediastinal disorders
Shortness of breath
6.2%
1/16 • Number of events 2 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).
12.5%
2/16 • Number of events 2 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).
Respiratory, thoracic and mediastinal disorders
Chest tightness
0.00%
0/16 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).
12.5%
2/16 • Number of events 2 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).
Respiratory, thoracic and mediastinal disorders
Chest pain
0.00%
0/16 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).
6.2%
1/16 • Number of events 1 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).
Nervous system disorders
Headache
0.00%
0/16 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).
6.2%
1/16 • Number of events 1 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).
Respiratory, thoracic and mediastinal disorders
Hemoptysis
12.5%
2/16 • Number of events 2 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).
0.00%
0/16 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).
Respiratory, thoracic and mediastinal disorders
Cough
6.2%
1/16 • Number of events 1 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).
0.00%
0/16 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).
Gastrointestinal disorders
Nausea
6.2%
1/16 • Number of events 1 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).
0.00%
0/16 • Adverse events: Baseline to 1 month. Mortality: Baseline to 3 months.
Adverse events specifically related to intervention administration were collected by way of medial record review as inpatient, and/or patient diary as an outpatient. Adverse events were screened for daily whilst an inpatient, and at the first scheduled follow up assessment as an outpatient at the point cessation of intervention (1 month). All-cause mortality was recorded across the entire study period (Baseline to 3 months).

Additional Information

Benjamin James Tarrant

Alfred Health

Phone: +61404455658

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place